Hosted on MSN

GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal

GSK will pay a subsidiary of HUTCHMED $110m upfront for a novel type of drug designed to selectively target solid tumours. Under the licensing deal, a subsidiary of GSK will gain global rights to the ...
ascopubs.org

A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after ...

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. This is an ASCO Meeting Abstract ...

Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate

Pfizer (PFE) and Medicus Pharma (MDCX) sign a licensing deal worth up to $1B for PF-08046031 ("CD228V"), an antibody drug conjugate. Read more here.